Longwood Capital Partners
Latest statistics and disclosures from Acuta Capital Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are TERN, PRAX, CDTX, OCUL, WHWK, and represent 61.74% of Acuta Capital Partners's stock portfolio.
- Added to shares of these 10 stocks: PRAX (+$9.8M), TERN (+$5.4M), NERV, TNGX, DSGN, CMPX, MAZE, MLTX, STRO, JAZZ.
- Started 7 new stock positions in KTTA, NERV, STRO, MAZE, TNGX, MLTX, DSGN.
- Reduced shares in these 10 stocks: TRML (-$13M), CDTX (-$12M), INSM, ASND, KRYS, COGT, OCUL, ARGX, FULC, DNTH.
- Sold out of its positions in ASND, COGT, FULC, KRYS, TRML.
- Acuta Capital Partners was a net seller of stock by $-8.5M.
- Acuta Capital Partners has $147M in assets under management (AUM), dropping by 52.20%.
- Central Index Key (CIK): 0001582844
Tip: Access up to 7 years of quarterly data
Positions held by Longwood Capital Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Acuta Capital Partners
Acuta Capital Partners holds 30 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Terns Pharmaceuticals (TERN) | 17.5 | $26M | +26% | 637k | 40.40 |
|
| Praxis Precision Medicines I (PRAX) | 16.6 | $25M | +66% | 83k | 294.74 |
|
| Cidara Therapeutics Com New (CDTX) | 13.4 | $20M | -37% | 89k | 220.89 |
|
| Ocular Therapeutix (OCUL) | 8.7 | $13M | -9% | 1.1M | 12.14 |
|
| Aadi Bioscience (WHWK) | 5.6 | $8.3M | 3.4M | 2.42 |
|
|
| Bright Minds Biosciences Com New (DRUG) | 4.5 | $6.6M | 85k | 78.04 |
|
|
| Compass Therapeutics (CMPX) | 4.0 | $5.9M | +30% | 1.1M | 5.37 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 3.3 | $4.9M | +15% | 29k | 170.00 |
|
| Insmed Com Par $.01 (INSM) | 3.1 | $4.5M | -32% | 26k | 174.04 |
|
| Argen Se - Sponsored Adr (ARGX) | 2.8 | $4.1M | -23% | 4.9k | 840.95 |
|
| Surrozen Com New (SRZN) | 2.7 | $4.0M | 178k | 22.60 |
|
|
| Amylyx Pharmaceuticals (AMLX) | 2.7 | $4.0M | 333k | 12.08 |
|
|
| Minerva Neurosciences Com New (NERV) | 1.9 | $2.9M | NEW | 710k | 4.02 |
|
| Tango Therapeutics (TNGX) | 1.7 | $2.5M | NEW | 283k | 8.86 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 1.7 | $2.5M | 455k | 5.50 |
|
|
| Zymeworks Del (ZYME) | 1.4 | $2.1M | 80k | 26.33 |
|
|
| Oculis Holding Ordinary Shares (OCS) | 1.4 | $2.0M | 102k | 19.97 |
|
|
| Design Therapeutics (DSGN) | 1.0 | $1.4M | NEW | 151k | 9.38 |
|
| Inhibrx Biosciences (INBX) | 0.9 | $1.3M | 16k | 79.00 |
|
|
| United Therapeutics Corporation (UTHR) | 0.8 | $1.1M | 2.3k | 487.25 |
|
|
| Verastem Com New (VSTM) | 0.8 | $1.1M | 143k | 7.72 |
|
|
| Maze Therapeatics (MAZE) | 0.6 | $829k | NEW | 20k | 41.43 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.5 | $781k | NEW | 59k | 13.18 |
|
| Sutro Biopharma (STRO) | 0.5 | $780k | NEW | 68k | 11.57 |
|
| Dianthus Therapeutics (DNTH) | 0.5 | $689k | -33% | 17k | 41.21 |
|
| Revolution Medicines (RVMD) | 0.5 | $670k | 8.4k | 79.65 |
|
|
| Lb Pharmaceuticals Com Shs (LBRX) | 0.5 | $668k | 30k | 22.26 |
|
|
| Pasithea Therapeutics Corp Com New (KTTA) | 0.4 | $581k | NEW | 450k | 1.29 |
|
| Unicycive Therapeutics (UNCY) | 0.2 | $346k | 60k | 5.77 |
|
|
| Nuvation Bio Inc -cw27 *w Exp 07/07/2027 (NUVB.WS) | 0.0 | $30k | 91k | 0.33 |
|
Past Filings by Acuta Capital Partners
SEC 13F filings are viewable for Acuta Capital Partners going back to 2014
- Acuta Capital Partners 2025 Q4 filed Feb. 17, 2026
- Acuta Capital Partners 2025 Q3 filed Nov. 14, 2025
- Acuta Capital Partners 2025 Q2 filed Aug. 14, 2025
- Acuta Capital Partners 2025 Q1 filed May 15, 2025
- Acuta Capital Partners 2024 Q4 filed Feb. 14, 2025
- Acuta Capital Partners 2024 Q3 filed Nov. 14, 2024
- Acuta Capital Partners 2024 Q2 filed Aug. 14, 2024
- Acuta Capital Partners 2024 Q1 filed May 15, 2024
- Acuta Capital Partners 2023 Q4 filed Feb. 14, 2024
- Acuta Capital Partners 2023 Q3 filed Nov. 14, 2023
- Acuta Capital Partners 2023 Q2 filed Aug. 14, 2023
- Acuta Capital Partners 2023 Q1 filed May 15, 2023
- Acuta Capital Partners 2022 Q4 filed Feb. 14, 2023
- Acuta Capital Partners 2022 Q3 filed Nov. 14, 2022
- Acuta Capital Partners 2022 Q2 filed Aug. 15, 2022
- Acuta Capital Partners 2022 Q1 filed May 16, 2022